Temporal Lobe Atrophy in Patients with Alzheimer Disease: A CT Study

D. K. Kido
E. D. Caine
M. LeMay
S. Ekholm
H. Booth
R. Panzer

CT was used to document temporal lobe atrophy in 39 patients who were diagnosed clinically as having Alzheimer disease; the results were compared with those from 29 healthy elderly control subjects who were matched for age and education. The diagnosis of Alzheimer disease was made according to clinical criteria consistent with those specified by an NINCDS workshop. These included detailed medical and neuropsychological assessments.

Temporal lobe atrophy was assessed by evaluating the temporal horns and sylvian cisterns. Temporal horn measurements greater than 3 mm occurred only in patients with Alzheimer disease while measurements less than or equal to this occurred in both Alzheimer patients and control subjects. Subjective evaluation of the sylvian cistern indicated that 24/29 controls had normal-appearing cisterns while only 5/39 Alzheimer patients had similar findings. In contrast to temporal horns, sylvian cisterns were more sensitive but less specific as discriminators between Alzheimer patients and normal controls.

The cerebral atrophy that occurs in patients with Alzheimer disease overlaps that which occurs in normal individuals during their sixth and seventh decades [1, 2]. Most attempts to differentiate morphologically these two groups with CT have focused on enlargement of the lateral ventricles and cerebral sulci. Several investigators have reported that linear and planar CT measurements of the lateral ventricles or ratios between the ventricles and cranium can differentiate Alzheimer disease from normal aging [3–5]. Others have disagreed [6, 7]. More recently, it has been suggested that volumetric measurements of the lateral ventricles can separate these two groups [8, 9]. Sulcal enlargement [10, 11], gray/white differentiation, and brain density have also been measured in an attempt to separate Alzheimer patients from control subjects, but these parameters have produced negative or controversial results [12–16].

Atrophy of the temporal lobe has been largely ignored as a CT indicator of Alzheimer disease despite pathologic studies that indicate that atrophy and neurofibrillary tangles frequently occur in that location [17–20]. The reason for this may be that atrophy in the frontal and parietal lobes, and subsequent sulcal and ventricular enlargement, is more prominent than similar changes in the temporal lobes. To determine whether temporal lobe atrophy can be used to differentiate individuals in the earlier stages of Alzheimer disease from normal control subjects, we reviewed CT scans obtained from Alzheimer patients and normal controls. Temporal lobe atrophy was determined by separately analyzing sylvian cistern and temporal horn enlargement. We related temporal lobe atrophy to cognitive and functional changes in Alzheimer patients to determine whether the CT indexes we used could detect patients in the earliest stages of their disease.

Materials and Methods

Twenty-nine normal control subjects and 39 patients with Alzheimer disease participated in this study. Informed consent was obtained from all individuals who were scanned for...
Few scans were taken with 1 year; mean age of Alzheimer disease (24) since the disease has been shown to have a maximum score of 13, modified from the control illness, subjects were excluded who had a history of alcoholism, psychiatric illness, head trauma, significant neurologic disease, or medical illness that affected mentation, or who were using medications with central actions or cognitive side effects. Thus, we recruited a physically healthy, functionally active group of control subjects. All normal control subjects and 36/39 Alzheimer patients were tested with the Mini-Mental State (MMS) examination (normal range = 24–30) [22], and all patients were also evaluated with a functional rating scale (maximum score = 13), modified from Shoulson and Fahn [23], that has been shown to correlate highly with CT changes in Huntington disease [24]. Functional ratings were not conducted for controls, since the selection criteria we used placed the sample at the “ceiling” of our test instrument.

Women outnumbered men in both the Alzheimer group (24/39) and the control group (18/29). In the 55–69 age group, there were 18 Alzheimer patients and 20 control subjects. The mean age of Alzheimer patients in this group was 63.6 ± 3.5 years as compared with controls, whose mean age was 61.9 ± 3.9 years. The controls in this group were better educated than the Alzheimer patients (15.3 ± 1.9 years of education versus 11.7 ± 4.7 years). In the 70+ age group, Alzheimer patients outnumbered controls (21 to nine). The mean age of Alzheimer patients in this older group was 75.5 ± 4.3 years; controls averaged 76.0 ± 6.3 years. Education for the Alzheimer group was 12.9 ± 4.0 years; controls averaged 13.7 ± 3.0 years.

The CT scans were performed on a GE 8800 scanner. The scans were taken 15° to Reid’s baseline by utilizing the scout view. The scans were usually obtained with 5-mm contiguous sections, but a few scans were taken with 10-mm sections and a 3-mm overlap. The scanner was operated at 120 kVp, 120 mA, and 2 sec.

The CT scans were subjectively examined for temporal lobe atrophy by separately evaluating the size of the temporal horns and sylvian cisterns. Temporal horn size was subjectively evaluated and assigned a number on a scale of 1 to 4 according to whether the horns appeared normal or slightly, moderately, or markedly enlarged. In addition, the symmetry of the temporal horns was noted. The anteroposterior diameter of the tip of the temporal horn, the width of the body of the temporal horn (anterior third), and the border between the body and tip of the temporal horns were measured in mm by using the cm scale on the corresponding CT image (Fig. 1). When the temporal horns were asymmetric, the larger side was measured.

The sylvian cisterns were subjectively evaluated and assigned a number on a scale of 1 to 4 according to whether they appeared to be normal or slightly, moderately, or markedly enlarged. The anteroposterior distance between the posterior inferior border of the frontal lobe and the anterior tip of the temporal lobe was measured in mm. In addition, the width of the sylvian cistern was measured 1 cm behind the tip of the temporal lobe (Fig. 2). Measurements were accurate to ± 1.0 mm. All CT measurements were conducted by neuroradiologists blinded to diagnosis, MMS score, and functional rating. The subject’s age was available to CT raters.

The ability of subjective ratings and objective measurements to discriminate at various cut-off levels between Alzheimer patients and controls was assessed through receiver operating characteristic (ROC) analysis [25]. The area under the ROC curves was used as an indicator of the overall discriminating ability of each measurement and to compare the different measures [26]. In this method, a perfect test has an area of 1.0 and a useless test has an area of 0.5.

To assess interrater reliability, subjective and objective measurements were obtained from two independent neuroradiologists on a representative sample of 18 Alzheimer patients and 24 controls. Their measurements were compared through Pearson correlation coefficients and discrimination through comparison of ROC curve areas for paired data [27].

Results

The temporal horns appeared subjectively enlarged in 26/39 Alzheimer patients while similar changes were present in only one control (Fig. 3). Differentiating normal from mild temporal horn enlargement was occasionally difficult, but differentiating mild from moderate temporal horn enlargement was not difficult (Fig. 4). Temporal horn asymmetry was
detected in 21/39 Alzheimer patients while similar changes were present in only 5/29 controls (Fig. 5).

Measurements of the tip, body, and border between the tip and body of the temporal horn in both Alzheimer patients and controls are given in Table 1. Linear measurements >3 mm in any of these three parameters, indicating the presence of temporal lobe atrophy, occurred only in Alzheimer patients. Measurements ≤3 mm occurred in both Alzheimer patients and control subjects. The one control who was subjectively judged to have mild temporal horn enlargement had an anteroposterior tip measurement of 3 mm, a body width of 2 mm, and an oblique border of 3 mm.

The Alzheimer patients with no subjective temporal horn enlargement demonstrated cognitive changes on their MMS tests; their mean score was 19.9 ± 5.8 (n = 12). Alzheimer patients with mild temporal horn enlargement (n = 14) had a mean MMS score of 14.5 ± 6.7; those with moderate enlargement (n = 7) had a mean score of 16.4 ± 6.4 (both MMS scores consistent with moderate dementia); and those with severe enlargement (n = 3) had a mean score of 8.0 ± 6.0 (severe dementia). The normal subjects had a mean MMS score of 29.2 ± 1.0 (n = 29). Functional ratings in Alzheimer patients were also diminished (normal-appearing temporal horns = 7.9 ± 2.5 [mild/moderate functional impairment], mild = 6.6 ± 3.4 [mild functional impairment], moderate = 7.1 ± 2.8, and severe = 4.0 ± 3.2 [moderate/severe functional impairment]). It was notable that in this cross-sectional study functional and cognitive scores tended to show a decline in

### TABLE 1: Temporal Horn Measurements

<table>
<thead>
<tr>
<th>Enlargement (mm)</th>
<th>Tip</th>
<th>Oblique Border</th>
<th>Body</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AD (Controls)</td>
<td>AD (Controls)</td>
<td>AD (Controls)</td>
</tr>
<tr>
<td>0</td>
<td>3 (4)</td>
<td>3 (6)</td>
<td>6 (18)</td>
</tr>
<tr>
<td>1</td>
<td>5 (16)</td>
<td>7 (11)</td>
<td>3 (6)</td>
</tr>
<tr>
<td>2</td>
<td>7 (7)</td>
<td>3 (11)</td>
<td>7 (2)</td>
</tr>
<tr>
<td>3</td>
<td>7 (2)</td>
<td>4 (1)</td>
<td>3 (0)</td>
</tr>
<tr>
<td>4</td>
<td>7 (0)</td>
<td>2 (0)</td>
<td>5 (0)</td>
</tr>
<tr>
<td>5</td>
<td>6 (0)</td>
<td>7 (0)</td>
<td>6 (0)</td>
</tr>
<tr>
<td>6</td>
<td>1 (0)</td>
<td>5 (0)</td>
<td>4 (0)</td>
</tr>
<tr>
<td>7</td>
<td>1 (0)</td>
<td>0 (0)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>8</td>
<td>2 (0)</td>
<td>5 (0)</td>
<td>3 (0)</td>
</tr>
<tr>
<td>9 and above</td>
<td>0 (0)</td>
<td>9 (0)</td>
<td>1 (0)</td>
</tr>
</tbody>
</table>

Note.—AD = Alzheimer disease patients.
relation to the full spectrum of CT changes as independent variables but proved insensitive to apparent differences between patients with mild and moderate temporal horn enlargement.

Subjective ratings showed that individuals with Alzheimer disease had larger-appearing sylvian cisterns than controls did (Fig. 6). These findings were corroborated objectively by two measurements (Table 2). First, the anteroposterior distance of the right anterior sylvian cistern was 2.7 mm greater in Alzheimer patients than in controls \((p < .001)\). Second, the width of the right anterior sylvian cistern was 2.9 mm greater in Alzheimer patients than in controls \((p < .0001)\). The measurements of the left sylvian cistern were similar to those on the right. Although the sylvian cisterns of 35/39 Alzheimer patients and 29/29 controls appeared grossly symmetric, minor asymmetries were frequently present (Fig. 7).

A comparison of the accuracy of classifying individuals as Alzheimer patients or control subjects by using the areas under the ROC curves showed no significant differences among the subjective and objective measurements. The areas varied from .80 ± .05 to .87 ± .04 \((p = NS)\). Although analysis based on a single cut-off level showed a trend for the sylvian cistern measure to be more sensitive and the temporal horn measure to be more specific, there were no differences in overall accuracy.

![Fig. 6.—Distribution of subjective sylvian cistern measurements in normal controls \((n = 29)\) and patients with Alzheimer disease \((n = 39)\).](image)

![Fig. 7.—65-year-old woman, normal control, with moderate sylvian cistern enlargement.](image)

Interrater reliability was good, with Pearson correlation coefficients ranging from .87 to .93 for the subjective and objective estimates. There was a trend for one reader to record higher subjective and objective measurements of atrophy, with a difference averaging 0.9 mm higher across all objective measurements. However, there were no significant differences in the two readers’ ability to discriminate between Alzheimer disease as measured by ROC curve areas.

**Discussion**

The temporal horn measurements were quite specific but insensitive for identifying Alzheimer disease in our population. Temporal horns larger than 3 mm occurred only in Alzheimer patients. In contrast, the sylvian cistern measurements tended to be sensitive but not specific. This combination of test operating characteristics suggests that use of both measurements might be worthwhile when it is important to discriminate between Alzheimer disease and normal aging. Thus, given its high sensitivity, a normal sylvian cistern might help rule out Alzheimer disease. Highly abnormal temporal horn measurements, given their high specificity, might help rule in disease. Our observations confirm an earlier study that indicated that multiple measurements of the temporal lobe and its surrounding structures can be used to separate Alzheimer patients from normal controls [20]. However, it remains to be determined whether measurements of the temporal lobe can be used to separate Alzheimer disease from the other diseases that cause dementia.

The CT representation of temporal lobe atrophy in Alzheimer patients results primarily from degenerative changes in the hippocampus, amygdala, and the adjacent white matter [2, 18, 28–30]. The amygdala and hippocampus are associated with memory, learning, and motivational changes, which are characteristic findings in patients with Alzheimer disease...
The CT findings we measured in the temporal lobe are indirect measurements of these structures, and it is not surprising that the MMS and functional scores in our cross-sectional study sample indicate that clinical changes occur in advance of detectable indirect morphologic CT changes. Therefore, CT scanning will continue to be used primarily to diagnose the 2–10% of patients with dementia who have treatable disorders [32, 33].

MR may be able to detect atrophy in the temporal lobes earlier than CT, because the former can image the hippocampus and amygdala directly, possibly allowing detection of more subtle structural changes. However, MR detection of hippocampal and amygdaloid atrophy must still be correlated with symptomatic changes. It remains to be determined whether grossly detectable pathology precedes clinically definable cognitive and functional declines. PET and SPECT appear to be more promising than either CT or MR, as they are able to measure abnormal metabolism and cerebral blood flow [34–36]. These two techniques may separate dementia patients with Alzheimer disease from those with multiinfarct dementia [37–39]. Unfortunately, PET continues to be an expensive research tool. SPECT, on the other hand, should provide a clinically useful tool when compounds such as [123I]-iodoamphetamine are used [39–40].

REFERENCES

19. LeMay M. CT changes in dementia: a review. AJNR 1986;7:841–853